Companies › VistaGen Therapeutics
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Psychiatry.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Fasedienol Nasal Spray | – | Phase 3 | Social Anxiety Disorder; Social Anxiety Disorder (SAD) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06358651 | Fasedienol Nasal Spray | Phase 3 | Social Anxiety Disorder | Psychiatry | Oct 2025 |
| NCT06615557 | Fasedienol Nasal Spray | Phase 3 | Social Anxiety Disorder (SAD) | Psychiatry | Apr 2026 |
| NCT06809179 | Fasedienol Nasal Spray | Phase 2 | Social Anxiety Disorder | Psychiatry | Jun 2026 |
Cash and short-term investments of $32m on 2026-06-30; operating cash outflow about $60m a year; runway about 6 months at that burn, to Jan 2027
Press releases filed as 8-K in the last year:
Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Reviva Pharmaceuticals Curemark Emalex Biosciences Boston Medical Group Transcend Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.